NZ755141A - Methods of treating bacterial infections - Google Patents

Methods of treating bacterial infections

Info

Publication number
NZ755141A
NZ755141A NZ755141A NZ75514118A NZ755141A NZ 755141 A NZ755141 A NZ 755141A NZ 755141 A NZ755141 A NZ 755141A NZ 75514118 A NZ75514118 A NZ 75514118A NZ 755141 A NZ755141 A NZ 755141A
Authority
NZ
New Zealand
Prior art keywords
methods
bacterial infections
treating bacterial
urinary tract
tract infection
Prior art date
Application number
NZ755141A
Other languages
English (en)
Inventor
Jeffrey Loutit
Michael Dudley
Elizabeth Morgan
Karen Fusaro
David Griffith
Olga Lomovskaya
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ755141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of NZ755141A publication Critical patent/NZ755141A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ755141A 2017-01-09 2018-01-08 Methods of treating bacterial infections NZ755141A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01
PCT/US2018/012839 WO2018129479A1 (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Publications (1)

Publication Number Publication Date
NZ755141A true NZ755141A (en) 2023-01-27

Family

ID=62791302

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ755141A NZ755141A (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Country Status (21)

Country Link
US (1) US12478606B2 (enExample)
EP (2) EP4212157A1 (enExample)
JP (2) JP7436206B2 (enExample)
KR (2) KR102768209B1 (enExample)
CN (1) CN110402139A (enExample)
AU (1) AU2018205327B2 (enExample)
BR (1) BR112019014089A2 (enExample)
CA (1) CA3048650A1 (enExample)
CL (2) CL2019001918A1 (enExample)
CO (1) CO2019008575A2 (enExample)
DK (1) DK3565551T3 (enExample)
ES (1) ES2979266T3 (enExample)
FI (1) FI3565551T3 (enExample)
HU (1) HUE066805T2 (enExample)
MX (2) MX390529B (enExample)
NZ (1) NZ755141A (enExample)
PH (1) PH12019501606A1 (enExample)
PL (1) PL3565551T3 (enExample)
PT (1) PT3565551T (enExample)
SG (1) SG11201906226YA (enExample)
WO (1) WO2018129479A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478606B2 (en) 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections
AU2018345317B2 (en) * 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections
WO2022026993A1 (en) * 2020-07-27 2022-02-03 Northwestern University Antimicrobial choice algorithm for urinary tract infections
CN117940127A (zh) * 2022-07-05 2024-04-26 塞戈瑞·弗拉基米罗维奇·西多连科 治疗多种耐药细菌感染的制剂
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy
JP2026517813A (ja) * 2023-05-02 2026-06-02 シプラ・リミテッド 医薬配合剤及び抗菌剤を含むその組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN105393011A (zh) * 2013-05-15 2016-03-09 舍弗勒技术股份两合公司 减少阻力的离合器板
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
US12478606B2 (en) 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections

Also Published As

Publication number Publication date
MX2019008281A (es) 2019-12-02
FI3565551T3 (fi) 2024-06-18
KR20240133785A (ko) 2024-09-04
CO2019008575A2 (es) 2019-08-30
EP3565551A1 (en) 2019-11-13
KR102768209B1 (ko) 2025-02-18
US20190336475A1 (en) 2019-11-07
EP3565551B1 (en) 2024-03-20
PH12019501606A1 (en) 2020-06-15
MX2022001704A (es) 2022-03-11
WO2018129479A1 (en) 2018-07-12
SG11201906226YA (en) 2019-08-27
CL2020001886A1 (es) 2020-12-18
CN110402139A (zh) 2019-11-01
JP2023012538A (ja) 2023-01-25
EP4212157A1 (en) 2023-07-19
US12478606B2 (en) 2025-11-25
KR20190104385A (ko) 2019-09-09
CL2019001918A1 (es) 2020-02-14
EP3565551A4 (en) 2020-09-23
ES2979266T3 (es) 2024-09-25
PT3565551T (pt) 2024-06-14
JP2020504154A (ja) 2020-02-06
BR112019014089A2 (pt) 2020-02-04
JP7436206B2 (ja) 2024-02-21
DK3565551T3 (da) 2024-06-17
AU2018205327B2 (en) 2023-11-30
AU2018205327A1 (en) 2019-07-25
PL3565551T3 (pl) 2024-09-23
CA3048650A1 (en) 2018-07-12
HUE066805T2 (hu) 2024-09-28
MX390529B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
PH12019501606A1 (en) Methods of treating bacterial infections
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MX2016009898A (es) Tratamientos para acne resistente.
MX2016006708A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2013006873A (es) Una composicion que comprende un agente antibiotico y un agente dispersante o un agente antiadhesivo.
MX2014004366A (es) Aceleracion de la recuperacion muscular despues de la atrofia muscular inducida por inmovilizacion.
NZ593111A (en) Antibacterial compounds
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
GB201020860D0 (en) Disulfiram formulation and uses thereof
BR112015027536A8 (pt) composição compreendendo bactérias ácidas lácticas para utilização no tratamento preventivo e/ou curativo de cistite recorrente.
FR2969495B1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
MY197898A (en) A composition comprising pic for treatment of cancer
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
EP4268899A3 (en) Ferritin nanoparticles comprising a chemotherapeutic agent
AU2010298020A8 (en) Combination
UA96541C2 (ru) Способ лечения синдрома преждевременной еякуляции
UA48606U (ru) Способ лечения больных негоспитальной пневмонией, соединенной со стеатозом печени

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: MELINTA THERAPEUTICS, INC., US

Effective date: 20210422

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20241217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JAN 2027 BY COMPUTER PACKAGES INC

Effective date: 20251217